NCT03071926: Metronomic PLD in Patients With Primary Endocrine Resistant ABC

NCT03071926
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable symptomatic central nervous system (CNS) metastases that require treatment
https://ClinicalTrials.gov/show/NCT03071926

Comments are closed.

Up ↑